ClinicalTrials.gg
Active, not recruitingNCT07256015Updated Nov 2, 2026

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bristol-Myers Squibb · Observational

How we know

Updated Nov 2, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Planned enrollment
12th of 14
200 · median 528
Started
2025
with 6 others
Observational
14 of 42
5 open now
Primary completion
2027-07
later than 3 of 13 live
Registered
41st of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 12th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 3 of the 13 other live ones, and was the 41st registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

03

Conditions studied

  • Psoriasis

Keywords

  • Moderate/Severe Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults diagnosed moderate/severe psoriasis who have already started treatment with deucravacitinib according to clinical practice and to reimbursement criteria determined by the National Drug Agency (AIFA) in Italy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
  • Patients have moderate to severe plaque psoriasis
  • Patients have signed form (ICF)

Exclusion criteria

Exclusion Criteria:

  • Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
  • Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Participants with moderate/severe psoriasis receiving deucravacitinib

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. The percentage of participants still receiving deucravacitinib treatment

    Time frame: Week 24 and 52

  2. Absolute Psoriasis Area and Severity Index (PASI)

    Time frame: Baseline and Weeks 16, 24 and 52

Secondary outcomes

  1. Participant age in years

    Time frame: Baseline

  2. Participant sex

    Time frame: Baseline

  3. Participant height in cm

    Time frame: Baseline

  4. Participant body mass index in kg/m2

    Time frame: Baseline

  5. Participant previous pathologies

    Time frame: Baseline

  6. Participan previous surgical procedures

    Time frame: Baseline

  7. Date of psoriasis diagnosis

    Time frame: Baseline

  8. Number of participants with physical examination according to body systems

    Time frame: Baseline

  9. Participant treatment history

    Treatment history to describe participants previous treatment(s) received for psoriasis and participants previous treatment(s) received not related to psoriasis

    Time frame: Baseline

  10. Participant comorbidities

    Time frame: Baseline

  11. Quality of life as assessed by the Dermatology Life Quality Index (DLQI) questionnaire

    Time frame: Baseline and Weeks 16, 24 and 52

  12. Change in symptoms as assessed by the Itch Numerical Rating Scale (Itch-NRS) score

    Time frame: Baseline and Weeks 16, 24 and 52

  13. Body Surface Area (BSA)

    Time frame: Baseline and Weeks 16, 24 and 52

  14. Static Physician's Global Assessment (sPGA) score

    Time frame: Baseline and Weeks 16, 24 and 52

  15. Scalp Specific Physician Global Assessment (ssPGA) score

    Time frame: Baseline and Weeks 16, 24 and 52

  16. Scalp Specific Physician Global Assessment (ssPGA) score 0/1

    Time frame: Baseline and Weeks 16, 24 and 52

  17. Absolute Psoriasis Area and Severity Index (PASI) 75 and 90

    Time frame: Baseline and Weeks 16, 24 and 52

  18. Concomitant psoriasis therapies received

    Time frame: Baseline and Weeks 16, 24 and 52

07

Study locations

1 site
  • Local Institution - 0001
    Verona, 37126, Italy
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 23 months is below that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Dec 1, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Jul 5, 2027
CompletionEst.
Aug 5, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 2, 2026
Sites
1 site added, 1 site removed
Show site
  • Local Institution - 0001 · Verona, Italy
Show 1 removed
  • Azienda Ospedaliera Universitaria Integrata Di Verona · Verona, Italy
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Local Institution - 0001 · Verona, Italy
    Show 1 removed
    • Azienda Ospedaliera Universitaria Integrata Di Verona · Verona, Italy
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07256015
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Aug 5, 2025
Primary completion
Jul 5, 2027 (estimated)
Completion
Aug 5, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion